Biotics 8 Reviews: Company Publishes Strain-Level Research Review of 20 Billion CFU Probiotic Formula for Men

8 For Men Limited details the science behind each of the 10 organisms in its three-capsule daily formula, and says strain-level research should not be read as proof of the finished product's effects

Review examines published evidence involving specifically identified probiotic strains and explains why findings from individual studies should not be interpreted as clinical proof of the finished Biotics 8 supplement

New York city, NY, September 17, 2026 — 8 For Men Limited, operator of the Biotics 8 dietary-supplement brand, has published a research review examining scientific literature associated with probiotic organisms listed in the Biotics 8 formula. The review focuses on a central issue in probiotic research: clinical findings involving a specifically identified strain cannot automatically be attributed to every product containing another strain of the same species.

The review was prepared to distinguish three separate types of information that are sometimes presented together in consumer discussions of probiotics: the species names appearing on supplement labels, the particular strains evaluated in published clinical trials, and evidence relating to a finished commercial formulation.

Biotics 8 is a multi-ingredient dietary supplement whose current public product information lists 10 probiotic organisms providing a combined 20 billion colony-forming units, or CFU, per daily serving. The formulation also includes chicory-derived prebiotic ingredients, digestive enzymes and vitamin D.

The newly published review does not represent a clinical trial of Biotics 8 and does not conclude that the finished product produces outcomes reported in studies involving separately manufactured probiotic preparations. Instead, it summarizes examples from the scientific literature to illustrate why strain identity, dose, study population, intervention length and formulation should be considered before findings are generalized to another product.

“Research concerning probiotics can become difficult to interpret when a species name on a supplement label is treated as though it identifies the same intervention used in a clinical study,” said Neil Grovers, Product Head at Biotics 8. “Our objective with this review is to make that distinction explicit. Research involving a named strain can provide useful scientific context, but it should not be presented as direct evidence for a different finished formula unless that formula has itself been appropriately studied.”

Why Strain Identification Matters in Probiotic Research

Probiotics are commonly identified scientifically by genus, species and strain. Strain designations typically add an alphanumeric identifier after the genus and species name.

That distinction can be important because microorganisms within the same species are not necessarily interchangeable in clinical research.

The National Institutes of Health Office of Dietary Supplements notes that some probiotic mechanisms are shared across microorganisms while other effects may be species-specific or strain-specific. Its professional fact sheet also states that clinical recommendations concerning probiotics need to account for the strain used and that pooling research involving different strains can produce misleading conclusions.

The same NIH resource notes that commercial probiotic supplements vary substantially in the microorganisms and doses they contain and that many finished commercial products have not themselves been evaluated in clinical studies.

For that reason, the presence of a species in Biotics 8 should not be interpreted as establishing that Biotics 8 will reproduce an outcome reported for a separately identified strain of that species.

Examples Illustrate the Difference Between Ingredient Research and Product Evidence

One example reviewed involves Lactobacillus acidophilus, now included within a broader body of research involving multiple identified strains.

A 2020 randomized, double-blind, placebo-controlled multicenter trial published in Nutrients evaluated Lactobacillus acidophilus DDS-1 in adults with irritable bowel syndrome. The study enrolled 330 adults and administered the specifically identified DDS-1 strain at a defined dose during the intervention. Researchers reported differences in several symptom measurements compared with placebo.

Those findings concern DDS-1 under the conditions of that particular study. They do not demonstrate that every L. acidophilus strain has the same properties, and they do not establish that Biotics 8 treats irritable bowel syndrome or produces the outcomes observed in that trial.

The review makes the same distinction for Bifidobacterium bifidum.

A randomized, double-blind, placebo-controlled study published in Alimentary Pharmacology & Therapeutics evaluated the specifically identified strain B. bifidum MIMBb75 in 122 people with irritable bowel syndrome. Researchers reported differences between the intervention and placebo groups across several measured outcomes.

Again, the evidence applies to the intervention that investigators actually studied. A product listing B. bifidum at the species level should not be assumed to contain MIMBb75 or to reproduce its clinical results unless the strain identity and finished formulation support that conclusion.

The literature also contains studies with more mixed findings.

A 2020 randomized, double-blind, placebo-controlled study involving 251 adults evaluated Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 individually against placebo. Changes in the study’s overall IBS symptom-severity measure were similar among groups, although researchers reported differences in certain subgroup and secondary measurements.

Including studies with mixed or negative primary outcomes is important because scientific evidence should not be reduced to selected positive findings. The review therefore treats the literature as context for understanding particular microorganisms rather than as a collection of claims about the Biotics 8 product.

Research on Saccharomyces boulardii Provides Another Example

The Biotics 8 ingredient information also lists Saccharomyces boulardii, a probiotic yeast that has been evaluated in multiple clinical settings.

A 2015 systematic review and meta-analysis examined 21 randomized controlled trials involving 4,780 participants and evaluated S. boulardii in relation to antibiotic-associated diarrhea. The pooled analysis reported a lower incidence among participants receiving the studied S. boulardii interventions than among control participants.

However, individual research findings depend on the preparation studied, population, dose, duration and clinical setting. Other controlled research has produced different findings in particular populations.

The review therefore does not describe Biotics 8 as preventing antibiotic-associated diarrhea. The presence of S. boulardii in an ingredient list is not equivalent to demonstrating that the complete Biotics 8 formulation produces an outcome observed with another preparation.

Know about Biotics 8 Ingredients on their official website.

CFU Count Is Only One Part of Probiotic Evaluation

The review also addresses interpretation of colony-forming units.

CFU is used to describe the number of viable microorganisms in a probiotic product. Biotics 8’s current public materials state that the daily serving provides a combined total of 20 billion CFU across 10 probiotic organisms.

A larger CFU number, however, should not independently be interpreted as evidence that one probiotic product provides greater health benefits than another.

The NIH Office of Dietary Supplements advises consumers and health professionals that potential effects depend on factors including the particular microorganisms present and their amounts. Research findings are also influenced by characteristics of the population studied, study design, duration and the outcome being measured.

The research review consequently does not rank Biotics 8 against other probiotic products according to CFU count or number of organisms.

Finished-Product Evidence Remains a Separate Question

A central conclusion of the review is that research involving individual ingredients and research involving a finished multi-ingredient product answer different scientific questions.

Biotics 8 combines multiple probiotic organisms with prebiotic ingredients, digestive enzymes and vitamin D. Studies evaluating one of those components independently cannot determine how the complete formulation performs as a combined product.

Demonstrating a specific clinical outcome for the complete formulation would require research designed to evaluate that formulation under defined conditions.

The company therefore states that references to published research should not be interpreted as evidence that Biotics 8 diagnoses, treats, cures or prevents any disease.

This distinction is consistent with U.S. regulatory principles governing dietary-supplement communications. The U.S. Food and Drug Administration distinguishes permitted dietary-supplement structure/function statements from claims that a product diagnoses, mitigates, treats, cures or prevents a disease. FDA also states that companies making dietary-supplement claims are responsible for ensuring that their claims are truthful and not misleading.

Safety and Individual Considerations

Probiotic products have an established history of use, but individual responses can differ.

The National Center for Complementary and Integrative Health notes that probiotics have an extensive history of apparently safe use in healthy people while also stating that detailed safety information remains limited for some products and populations. Risk can be greater for people who are seriously ill or have compromised immune systems.

Consumers with significant medical conditions, those taking prescription medications, people who are pregnant or breastfeeding, and individuals receiving medical treatment should discuss dietary-supplement use with an appropriate healthcare professional.

Persistent or severe gastrointestinal symptoms should be medically evaluated rather than self-treated on the basis of information about a dietary supplement.

Frequently Asked Questions

Does the research review show that Biotics 8 treats IBS or another gastrointestinal disease?

No. The studies discussed in the review evaluated particular strains, preparations and research populations. The review does not report a clinical trial of the complete Biotics 8 formulation. Findings involving strains such as L. acidophilus DDS-1 or B. bifidum MIMBb75 should not be interpreted as proof that Biotics 8 produces the same outcomes. Biotics 8 is marketed as a dietary supplement and is not intended to diagnose, treat, cure or prevent disease.

Are a probiotic species and probiotic strain the same thing?

No. A species name identifies a broader taxonomic category, while a strain designation identifies a more specific microorganism within that species. For example, a clinical study may examine a particular strain carrying an additional identifier. Research involving that identified strain cannot automatically establish identical clinical effects for every other strain belonging to the same species.

Does 20 billion CFU mean Biotics 8 is more effective than a product with a lower CFU count?

No such conclusion can be made from CFU count alone. CFU indicates the number of viable microorganisms, but scientific evaluation also depends on the identity of the microorganisms, amount of each organism, formulation, study population and health outcome under investigation. A higher numerical CFU value does not by itself demonstrate greater clinical benefit.

How should consumers interpret studies cited in connection with probiotic ingredients?

Ingredient research is best understood as scientific background rather than automatic validation of a finished supplement. Consumers should check whether a study evaluated the same genus, species and strain, at a comparable dose and in an appropriate population. Research involving another strain or another formulation should not be represented as direct evidence for Biotics 8. People seeking guidance for a medical condition should consult a qualified healthcare professional rather than relying on supplement marketing or ingredient research alone.

About 8 For Men Limited

8 For Men Limited is a UK-based company and the operator of Biotics 8. The company provides dietary-supplement products and related product information through the Biotics 8 brand. Biotics 8 is a multi-ingredient probiotic dietary supplement containing probiotic organisms together with prebiotic ingredients, digestive enzymes and vitamin D. Product formulation, directions and other product information should be confirmed against the current label and official company materials.

Media Contact

Neil Grovers, Product Head, Biotics 8
9 Manor House Court, Chesterfield, S41 7GY
United Kingdom
Email: support@biotics8.com
Phone: +44 191 743 4476

Research References

1. National Institutes of Health, Office of Dietary Supplements. Probiotics — Health Professional Fact Sheet.

2. Martoni CJ, Srivastava S, Leyer G. “Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.” Nutrients. 2020;12(2):363. PMID: 32019158.

3. Lewis ED, et al. “Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Study.” Nutrients. 2020;12(4):1159. PMID: 32326347.

4. Guglielmetti S, et al. “Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life.” Alimentary Pharmacology & Therapeutics. 2011. PMID: 21418261.

5. Szajewska H, Kołodziej M. “Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.” Alimentary Pharmacology & Therapeutics. 2015. PMID: 26216624.

6. U.S. Food and Drug Administration. Structure/Function Claims and dietary-supplement claims guidance.

7. National Center for Complementary and Integrative Health. Probiotics: Usefulness and Safety.

Regulatory Notice: Biotics 8 is a dietary supplement. Statements concerning published studies of individual microorganisms or ingredients should not be interpreted as evidence that the finished product diagnoses, treats, cures or prevents any disease.

Media gallery